3'-[4-(2-piperidin-1-ylethoxy)phenyl]spiro[2,3-dihydroindene-1,1'-indene]-5,5'-diol

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 3'-[4-(2-piperidin-1-ylethoxy)phenyl]spiro[2,3-dihydroindene-1,1'-indene]-5,5'-diol
• 化学式: C₃₀H₃₁NO₃
• 分子量: 453.581
• InChiKey: MHJYBRXRPIGQJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-methoxy-2-(5-methoxy-2,3-dihydro-1H-inden-1-yl)benzoyl chloride 在 正丁基锂 、 Rh2(μ-acetate)4(H2O) 、 4-乙酰氨基苯磺酰叠氮 、 双(三甲基硅烷基)氨基钾 、 对甲苯磺酸 、 三乙胺 、 二苯基膦 作用下， 以 四氢呋喃 、 正己烷 、 水 、 二甲基亚砜 、 甲苯 、 乙腈 为溶剂， 反应 26.5h， 生成 3'-[4-(2-piperidin-1-ylethoxy)phenyl]spiro[2,3-dihydroindene-1,1'-indene]-5,5'-diol
  参考文献：
  名称：

  Discovery and Preclinical Characterization of (+)-3-[4-(1- Piperidinoethoxy)phenyl]spiro[indene- 1,1‘-indane]-5,5‘-diol Hydrochloride:  A Promising Nonsteroidal Estrogen Receptor Agonist for Hot Flush

  摘要：

  In our studies of the development of a novel class of selective estrogen receptor modulators, (+)-3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1'-indane]-5,5'-diol hydrochloride (1) was found to be an estrogen receptor ligand with beneficial effects in rat models for human hot flush. Moreover, 1 was found to have beneficial effects on lipid and bone metabolism while maintaining marginal effects on the uterus and breasts. These findings suggest that 1 would provide a new treatment for hot flush.

  DOI：

  10.1021/jm034134+

文献信息

• Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
  申请人：Watanabe Nobuhide

  公开号：US20050256308A1

  公开（公告）日：2005-11-17

  A spiro compound represented by the following formula (I) wherein R 1 and R 2 are the same or different and each is a hydrogen atom, a chlorine atom and the like, n is 1, 2 or 3, a bond containing a broken line is a single bond or a double bond, A is —X—(CH 2 ) q —N(R 3 )(R 4 ); a group represented by the following formula (a) and the like, wherein X is an oxygen atom or a sulfur atom, q is 2 or 3, R 3 and R 4 are the same or different and each is a C 1-6 alkyl group and the like, or R 3 and R 4 optionally form, together with the adjacent nitrogen atom, a piperidine ring and the like optionally substituted by one or two C 1-6 alkyl and the like, R 5 is a C 1-6 alkyl group and the like, R 6 is a hydrogen atom and the like, and r and t are each independently one or two, or a pharmaceutically acceptable acid addition salt thereof. The compound is useful as a selective estrogen receptor modulator having a climacteric syndrome-ameliorating effect, and can be expected to be a drug for the prophylaxis and/or treatment of osteoporosis, climacteric syndrome and breast cancer.

  以下式子(I)所表示的螺环化合物，其中R1和R2相同或不同，分别为氢原子，氯原子等，n为1、2或3，含有断线的键为单键或双键，A为—X—(CH2)q—N(R3)(R4)；一种由以下式子(a)表示的基团等，其中X为氧原子或硫原子，q为2或3，R3和R4相同或不同，分别为C1-6烷基等，或R3和R4可以与相邻的氮原子共同形成哌嗪环等，可选地被1或2个C1-6烷基等取代，R5为C1-6烷基等，R6为氢原子等，r和t各自独立地为1或2，或其药学上可接受的酸盐。该化合物可作为具有缓解更年期综合症作用的选择性雌激素受体调节剂，并可望成为预防和/或治疗骨质疏松症、更年期综合症和乳腺癌的药物。
• SPIRO COMPOUNDS, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THE COMPOUNDS
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP1559707A1

  公开（公告）日：2005-08-03

  A spiro compound represented by the following formula (I) wherein R1 and R2 are the same or different and each is a hydrogen atom, a chlorine atom and the like, n is 1, 2 or 3, a bond containing a broken line is a single bond or a double bond, A is -X-(CH2)q-N(R3)(R4); a group represented by the following formula (a) and the like, wherein X is an oxygen atom or a sulfur atom, q is 2 or 3, R3 and R4 are the same or different and each is a C1-6 alkyl group and the like, or R3 and R4 optionally form, together with the adjacent nitrogen atom, a piperidine ring and the like optionally substituted by one or two C1-6 alkyl and the like, R5 is a C1-6 alkyl group and the like, R6 is a hydrogen atom and the like, and r and t are each independently one or two, or a pharmaceutically acceptable acid addition salt thereof. The compound is useful as a selective estrogen receptor modulator having a climacteric syndrome-ameliorating effect, and can be expected to be a drug for the prophylaxis and/or treatment of osteoporosis, climacteric syndrome and breast cancer.

  下式(I)代表的螺环化合物 其中 R1 和 R2 相同或不同，各自为氢原子、氯原子等，n 为 1、2 或 3，含有断线的键为单键或双键，A 为 -X-(CH2)q-N(R3)(R4)；下式（a）代表的基团 及类似物，其中 X 是氧原子或硫原子，q 是 2 或 3，R3 和 R4 相同或不同且各自是 C1-6 烷基及类似物，或 R3 和 R4 与相邻的氮原子一起可选地形成可选地被一个或两个 C1-6 烷基及类似物取代的哌啶环及类似物，R5 是 C1-6 烷基及类似物，R6 是氢原子及类似物，r 和 t 独立地各自是一个或两个，或其药学上可接受的酸加成盐。该化合物可用作选择性雌激素受体调节剂，具有改善更年期综合征的作用，可望成为预防和/或治疗骨质疏松症、更年期综合征和乳腺癌的药物。
• Discovery and Preclinical Characterization of (+)-3-[4-(1- Piperidinoethoxy)phenyl]spiro[indene- 1,1‘-indane]-5,5‘-diol Hydrochloride:  A Promising Nonsteroidal Estrogen Receptor Agonist for Hot Flush
  作者：Nobuhide Watanabe、Akihisa Ikeno、Hisao Minato、Hiroshi Nakagawa、Chie Kohayakawa、Jun-ichi Tsuji

  DOI：10.1021/jm034134+

  日期：2003.9.1

  In our studies of the development of a novel class of selective estrogen receptor modulators, (+)-3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1'-indane]-5,5'-diol hydrochloride (1) was found to be an estrogen receptor ligand with beneficial effects in rat models for human hot flush. Moreover, 1 was found to have beneficial effects on lipid and bone metabolism while maintaining marginal effects on the uterus and breasts. These findings suggest that 1 would provide a new treatment for hot flush.